Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers. Background: The INSIGHT study evaluates feasibility ...
Hosted on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Patients who depend on antibody drugs often spend long hours in infusion centers. These medicines are vital for treating many cancers, autoimmune disorders and infectious diseases, but current ...
The U.S. FDA approved Merck & Co. Inc.’s Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection on Sept. 19, making it the first and only subcutaneously (SC)-administered immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results